P/E at 36.08 vs Industry's 37.22: What the Data Shows for Sun Pharmaceutical Industries Ltd

1 hour ago

Share Via

A price-to-earnings ratio of 36.08 against an industry average of 37.22 indicates that Sun Pharmaceutical Industries Ltd trades at a slight discount to its sector peers. Previously rated Buy by MarketsMojo, the company’s rating was reassessed on 03 Sep 2026. While the one-year return of 19.31% comfortably outpaces the Sensex’s negative 6.17%, the short-term momentum shows a more nuanced picture with recent underperformance — what is the current rating?

Valuation Picture: Slight Discount Amid Sector Premiums

The current P/E of 36.08 for Sun Pharmaceutical Industries Ltd is marginally below the Pharmaceuticals & Biotechnology industry average of 37.22. This subtle discount contrasts with many large-cap peers that often trade at premiums exceeding 1.5x sector averages. The valuation suggests that the market is pricing in steady earnings growth but with some caution, possibly reflecting recent volatility in the sector or company-specific factors. The market capitalisation stands at ₹4,55,826 crores, underscoring its stature as a large-cap heavyweight within the pharmaceuticals space.

Performance Across Timeframes: Divergent Momentum

Examining the stock’s returns reveals a compelling divergence between short and long-term performance. Over the past year, Sun Pharmaceutical Industries Ltd has delivered a robust 19.31% gain, significantly outperforming the Sensex’s decline of 6.17%. This outperformance extends over longer horizons as well, with three-year and five-year returns of 66.77% and 142.61% respectively, both well ahead of the Sensex’s 13.83% and 30.14% gains over the same periods.

However, the recent trend is less encouraging. The stock has declined 2.33% over the past week and 3.26% over the last month, slightly underperforming the Sensex’s respective falls of 1.48% and 3.43%. Interestingly, the three-month return remains positive at 5.42%, outperforming the Sensex’s 3.10% rise, indicating some resilience despite short-term weakness. Year-to-date, the stock has gained 9.64%, contrasting with the Sensex’s 11.05% decline — is this a sign of underlying strength or temporary relief?

Moving Average Configuration: Mixed Technical Signals

The technical picture for Sun Pharmaceutical Industries Ltd is nuanced. The stock currently trades above its 100-day and 200-day moving averages, signalling a longer-term uptrend. However, it remains below the 5-day, 20-day, and 50-day moving averages, suggesting short-term pressure and a possible consolidation phase. This configuration often indicates a recent pullback within a broader upward trend, but it also raises questions about the sustainability of the bounce — is this a genuine recovery or a dead-cat bounce? The interplay between these moving averages will be critical to watch in the coming weeks.

Sector Context: Mixed Results in Pharmaceuticals & Biotechnology

The Pharmaceuticals & Biotechnology sector has seen a mixed bag of results recently. Out of 34 stocks that have declared results, 14 reported positive outcomes, 15 remained flat, and 5 posted negative results. This distribution highlights a sector grappling with varied operational and market challenges. Within this environment, Sun Pharmaceutical Industries Ltd has managed to maintain relative stability, though its recent underperformance relative to the sector’s average daily change of -0.25% (stock down 0.75%) suggests some headwinds.

Rating Reassessment: Previously Rated Buy

MarketsMOJO had previously assigned a Buy rating to Sun Pharmaceutical Industries Ltd. This rating was updated on 03 Sep 2026, reflecting a reassessment of the company’s fundamentals and market position. The current Mojo Score stands at 67.0, with a Mojo Grade of Hold. The rating change invites investors to consider the implications of the valuation-performance tension and the mixed technical signals — should investors in Sun Pharmaceutical Industries Ltd hold, buy more, or reconsider?

Collective Data Insights: Balancing Valuation and Momentum

Bringing together the valuation, performance, technical, and sector data, Sun Pharmaceutical Industries Ltd presents a complex picture. The stock’s P/E ratio near the industry average suggests fair valuation, yet the recent short-term underperformance and mixed moving average configuration point to caution. Long-term returns remain strong, underscoring the company’s resilience in a competitive sector. The sector’s mixed results further complicate the outlook, emphasising the importance of monitoring upcoming earnings and market developments closely.

Conclusion: A Stock at a Crossroads

The data-driven analysis of Sun Pharmaceutical Industries Ltd reveals a stock balancing on the edge of valuation fairness and short-term technical uncertainty. Its long-term performance remains impressive, but recent price action and sector dynamics suggest a period of consolidation or reassessment. Investors may find value in revisiting the company’s fundamentals and monitoring how the stock navigates its moving averages in the near term — what is the current rating?

Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today

{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)

MOJO SCORE